Peptide Research Profile

Tesamorelin

Trans-3-Hexenoic Acid–GHRH(1-44)–NH₂ — Stabilized Growth Hormone-Releasing Hormone Analog

Evidence Grade: FDA Approved (Egrifta®) · HIV Lipodystrophy Indication

A synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus. FDA-approved as Egrifta® (2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Unlike exogenous GH, tesamorelin stimulates the pituitary to produce GH physiologically, preserving the pulsatile secretion pattern and negative feedback loops. Off-label interest exists for body composition, cognitive preservation in aging, and NAFLD.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Off-label uses described here are not FDA-endorsed. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

GHRH Analog

44-amino-acid stabilized analog of endogenous GHRH(1-44)-NH₂

FDA Status

Approved (2010)

Egrifta® — HIV-associated lipodystrophy (excess abdominal visceral fat)

Evidence Level

Phase 3 RCT

Two pivotal Phase 3 trials • n=816 combined • Approved by FDA

Key Pathway

GHRH-R → Pituitary GH

Stimulates endogenous GH secretion via pituitary somatotrophs — preserves physiologic pulsatility

Pharmacology

Mechanism of action

Tesamorelin is a GHRH receptor agonist that stimulates the anterior pituitary gland to synthesize and secrete growth hormone in a physiologically pulsatile pattern. Unlike direct GH administration (which suppresses endogenous GH production and delivers supraphysiologic, non-pulsatile levels), tesamorelin works through the body’s own regulatory system. The pituitary retains feedback control through somatostatin, IGF-1, and GH itself, creating a ceiling effect that limits excessive GH exposure. This is the key pharmacological distinction from exogenous GH injections.

Subcutaneous Injection & Systemic Distribution

Tesamorelin is administered as a daily subcutaneous injection (2 mg). The trans-3-hexenoic acid N-terminal modification protects against aminopeptidase degradation, extending the functional half-life to approximately 26 minutes (vs. ~7 minutes for native GHRH). While this half-life is short, it is sufficient to trigger a GH secretion pulse lasting 2–4 hours. The peptide is distributed via systemic circulation to the anterior pituitary, where it binds GHRH receptors on somatotroph cells.

PK details: Subcutaneous bioavailability is approximately 4% due to local enzymatic degradation at the injection site. Despite this low bioavailability, sufficient peptide reaches the pituitary to reliably stimulate GH release. Peak plasma tesamorelin concentration occurs at ~15 minutes post-injection. The short plasma half-life is actually advantageous — it creates a discrete stimulus pulse rather than sustained receptor activation, preserving the pulsatile GH pattern that mimics natural physiology. Volume of distribution is approximately 9.4 L in HIV patients.

GHRH Receptor Activation on Pituitary Somatotrophs

Tesamorelin binds the GHRH receptor (GHRHR), a Class B G-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Receptor activation triggers Gαs-mediated adenylyl cyclase activation, raising intracellular cAMP. This activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein), driving GH gene transcription and granule exocytosis. The result is a GH secretion pulse within 15–30 minutes of injection.

Receptor signaling cascade: GHRHR couples to Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → GH gene promoter activation. Additionally, cAMP activates Epac (exchange protein directly activated by cAMP), which modulates Pit-1 transcription factor activity — Pit-1 is essential for somatotroph differentiation and GH gene expression. The GHRH receptor also signals through PLC-β/IP3/Ca²⁺ to trigger immediate GH granule release (exocytosis) independent of new gene transcription. This dual mechanism produces both an acute GH burst (granule release) and sustained GH production (gene transcription).

Physiologic GH Pulse & IGF-1 Generation

The GH pulse stimulated by tesamorelin triggers hepatic IGF-1 production via JAK2/STAT5 signaling in hepatocytes. IGF-1 is the primary mediator of GH’s anabolic and metabolic effects. Crucially, the pulsatile GH pattern preserves somatostatin feedback — between pulses, somatostatin from the hypothalamus inhibits further GH release, preventing the sustained elevation seen with exogenous GH. Mean IGF-1 levels rise approximately 50–100 ng/mL over baseline on tesamorelin, remaining within or near the physiologic range.

GH pulsatility importance: Continuous GH exposure (as with exogenous GH) downregulates GH receptors in target tissues and produces different gene expression patterns than pulsatile exposure. Pulsatile GH preferentially activates STAT5b (which drives IGF-1, height-related growth, and metabolic regulation), while continuous GH preferentially activates STAT5a and STAT3 (associated with different, potentially less favorable metabolic profiles). The intermittent GHRH stimulus from daily tesamorelin preserves the natural pulse architecture, which may explain why it has fewer side effects than equivalent IGF-1 elevations from exogenous GH.

Visceral Adipose Tissue Reduction

GH and IGF-1 promote lipolysis in visceral adipose tissue (VAT) through hormone-sensitive lipase (HSL) activation and perilipin phosphorylation. GH directly activates JAK2/STAT5 signaling in adipocytes, increasing lipolytic gene expression while suppressing lipogenic genes (LPL, FAS). The preferential reduction of visceral vs. subcutaneous fat is a consistent finding across tesamorelin trials — VAT decreased by 15–18% while subcutaneous fat was relatively spared.

Visceral selectivity: Visceral adipocytes express more GH receptors and have higher lipolytic sensitivity than subcutaneous adipocytes. GH-stimulated lipolysis in VAT involves β-adrenergic receptor upregulation and PKA-mediated HSL phosphorylation at Ser563, Ser659, and Ser660. Additionally, GH reduces insulin signaling in visceral fat (via SOCS protein induction), decreasing insulin’s anti-lipolytic effect. The net result is a preferential mobilization of visceral fat stores. This is metabolically favorable because VAT is more strongly associated with insulin resistance, cardiovascular risk, and hepatic steatosis than subcutaneous fat.

Hepatic & Cognitive Effects (Off-Label Interest)

Tesamorelin has shown promise in two off-label domains: NAFLD/liver fat reduction and cognitive preservation. In a 12-month RCT in HIV patients with NAFLD, tesamorelin reduced hepatic fat fraction by 37% and prevented fibrosis progression. Separately, a Harvard-led RCT in cognitively normal older adults showed tesamorelin preserved executive function and verbal memory compared to placebo over 20 weeks, potentially through IGF-1-mediated neuroprotection.

Cognitive mechanism: IGF-1 crosses the blood-brain barrier and binds IGF-1 receptors on hippocampal and prefrontal cortex neurons. IGF-1R activation promotes neuronal survival (PI3K/Akt), synaptic plasticity (MAPK/ERK), and BDNF expression. Age-related GH/IGF-1 decline correlates with cognitive decline in epidemiological studies. The Stanley et al. (2015) trial at Harvard showed tesamorelin-treated adults maintained performance on executive function tasks while placebo-treated adults declined — the effect was neuroprotective (preventing decline) rather than nootropic (enhancing above baseline). Hepatic mechanism: GH directly suppresses hepatic de novo lipogenesis via STAT5-mediated downregulation of SREBP-1c and ChREBP transcription factors. It simultaneously increases hepatic fatty acid oxidation through AMPK/CPT1 activation.

Administration

Delivery routes

Subcutaneous Injection

FDA-Approved Route

Daily subcutaneous injection in the abdomen. Administered via a reconstituted vial (lyophilized powder + sterile water). The injection site should be rotated to prevent lipohypertrophy. This is the only FDA-approved delivery route. The daily dosing schedule is necessary because each injection produces a single GH pulse; the pulsatile pattern depends on daily stimulation.

Intravenous

Research Only

IV administration produces a faster, more intense GH pulse and is used in GHRH stimulation testing (diagnostic) to assess pituitary GH reserve. Not used therapeutically because the bolus effect is too intense and doesn’t replicate physiologic pulsatility. IV GHRH stimulation tests are standard in endocrinology for diagnosing GH deficiency.

Oral / Sublingual

Not Viable

A 44-amino-acid peptide is completely degraded by gastrointestinal proteases. No oral or sublingual formulation exists or is in development. Oral GH secretagogues (like MK-677/ibutamoren) exist as an alternative oral route to stimulate GH release, but these work through a different receptor (ghrelin receptor) and have a different side-effect profile.

Intranasal

Not Developed

The large molecular size of tesamorelin (44 amino acids, ~5 kDa) makes nasal absorption inefficient. Unlike small heptapeptides like Selank, tesamorelin would have very poor nasal bioavailability. No intranasal formulation has been tested.

Protocols

Dosing reference

Tesamorelin dosing is established through FDA-approved prescribing information and two Phase 3 pivotal trials. The approved dose is straightforward with no titration required.

Context	Dose	Frequency	Source
HIV lipodystrophy (FDA-approved)	2 mg/day Subcutaneous, abdomen	Once daily	FDA prescribing information (Egrifta®)
NAFLD (research)	2 mg/day Same as approved dose	Once daily for 12 months	Stanley et al., Lancet HIV 2019
Cognitive study	2 mg/day Same as approved dose	Once daily for 20 weeks	Stanley et al., Arch Neurol 2015
Off-label anti-aging (community)	1–2 mg/day Some practitioners use lower doses	Once daily, various cycle lengths	Clinical practice / anecdotal

Important: The FDA-approved dose is 2 mg daily with no titration. Treatment should be discontinued if no reduction in visceral fat is observed after 6 months. IGF-1 levels should be monitored periodically — if IGF-1 exceeds the age-adjusted upper limit of normal, dose reduction or discontinuation should be considered. Tesamorelin is contraindicated in pregnancy (FDA Category X) and in patients with active malignancy.

Outcomes

Benefits & side effects

Reported Benefits

Visceral Fat Reduction

Phase 3 trials demonstrated 15–18% reduction in visceral adipose tissue (by CT scan) after 26 weeks of treatment. This is selective for metabolically dangerous visceral fat, with minimal effect on subcutaneous fat or lean mass. The effect is maintained with continued treatment but reverses upon discontinuation.

Two Phase 3 RCTs • n=816 combined • FDA-approved indication

Liver Fat Reduction (NAFLD)

In a 12-month RCT (n=61), tesamorelin reduced hepatic fat fraction by 37% vs. an increase of 9% in the placebo group. Importantly, it prevented fibrosis progression — 34% of placebo patients showed fibrosis worsening vs. 8% on tesamorelin. This is among the most compelling hepatic data for any GH-axis intervention.

RCT • Stanley et al., Lancet HIV 2019 • n=61 • 12 months

Cognitive Preservation

In healthy older adults (60–80 years), 20 weeks of tesamorelin preserved executive function and verbal memory compared to placebo-treated decline. The effect correlated with IGF-1 level increases. This suggests GH-axis stimulation may protect against age-related cognitive decline, though the mechanism is neuroprotective rather than enhancing.

RCT • Stanley et al., Arch Neurol 2015 • n=152 • 20 weeks

Physiologic GH Pattern Preserved

Unlike exogenous GH, tesamorelin preserves pulsatile GH secretion, somatostatin feedback, and the GH/IGF-1 axis negative feedback loop. This means lower risk of GH-excess side effects (edema, carpal tunnel, insulin resistance, joint pain) compared to equivalent GH doses. The body retains its ability to regulate GH output.

Pharmacodynamic studies • FDA review data

Adverse Effects & Risks

Injection Site Reactions

Erythema, pruritus, and induration at the injection site are the most commonly reported adverse events (up to 13% of patients). Reactions are generally mild and transient. Rotating injection sites reduces frequency. Lipohypertrophy can occur with repeated injection at the same site.

Phase 3 trial AE data • Mild, manageable

Arthralgia & Peripheral Edema

Joint pain (up to 13%) and mild peripheral edema (6%) are class effects of GH elevation. These are dose-related and reflect the anabolic and fluid-retentive effects of GH/IGF-1. Usually mild and may resolve with continued treatment as the body adjusts to the new GH setpoint.

Phase 3 AE data • GH-class effect • Generally mild

Transient Glucose Elevation

GH is a counter-regulatory hormone that induces insulin resistance. Some patients experience modest increases in fasting glucose and HbA1c during treatment. In the Phase 3 trials, the effect was statistically significant but clinically modest (HbA1c increase ~0.1–0.2%). More concerning in patients with pre-existing diabetes or insulin resistance.

Phase 3 • Clinically modest • Monitor in diabetic patients

Theoretical Cancer Risk

IGF-1 is a growth factor that promotes cell proliferation and inhibits apoptosis. Epidemiological studies associate higher circulating IGF-1 with increased risk of certain cancers (prostate, breast, colorectal). Tesamorelin is contraindicated in patients with active malignancy. Long-term cancer surveillance data from tesamorelin use specifically is limited but reassuring to date.

Theoretical — based on IGF-1 biology • Contraindicated with active malignancy

Reversibility Upon Discontinuation

Visceral fat reduction reverses when tesamorelin is stopped. In extension studies, VAT returned toward baseline within 3–6 months of discontinuation. This means tesamorelin requires ongoing treatment to maintain benefits, similar to other chronic metabolic therapies. The reversibility is a limitation, not a side effect per se, but patients should understand this.

Phase 3 extension data • Benefits require continued treatment

Evidence Base

Key studies

Phase 3 Pivotal RCT

Tesamorelin for Treatment of Visceral Adiposity in HIV

Falutz et al. • JAMA • 2007 • n=412

Design & Findings

26-week, double-blind, placebo-controlled trial in HIV-infected adults with excess abdominal fat. Tesamorelin 2 mg/day reduced trunk fat by 15.2% (CT-measured VAT) vs. a 5% increase in placebo. IGF-1 increased by ~80 ng/mL. No significant changes in glucose, lipids, or HIV viral parameters. Lean body mass was preserved.

Significance

First pivotal trial leading to FDA approval. Established tesamorelin as the only FDA-approved treatment for HIV-associated abdominal lipohypertrophy. Demonstrated VAT selectivity with lean mass preservation.

Limitations

26-week duration. HIV-specific population may not generalize to non-HIV lipodystrophy. CT measurement at single time point. No hepatic or cardiovascular hard outcomes measured. Funded by the manufacturer (Theratechnologies).

View on PubMed

Randomized Controlled Trial — NAFLD

Tesamorelin Reduces Liver Fat and Fibrosis Progression in HIV

Stanley et al. • Lancet HIV • 2019 • n=61

Design & Findings

12-month RCT in HIV patients with NAFLD. Tesamorelin reduced hepatic fat fraction by 37.4% vs. +9.5% in placebo (MR spectroscopy). Fibrosis progression occurred in 34% of placebo vs. 8% of tesamorelin patients (transient elastography). Hepatic de novo lipogenesis was reduced by tesamorelin.

Significance

Strongest evidence for GH-axis intervention in NAFLD/MASLD. The fibrosis-prevention data is particularly compelling because fibrosis is the strongest predictor of liver-related mortality. Opens the door for non-HIV NAFLD trials.

Limitations

Small sample (n=61). HIV-specific population. Non-invasive fibrosis assessment (elastography, not biopsy). 12-month duration — longer-term fibrosis outcomes unknown. Single-center study.

View on PubMed

Randomized Controlled Trial — Cognition

Tesamorelin and Cognition in Healthy Older Adults

Stanley et al. • Archives of Neurology • 2015 • n=152

Design & Findings

20-week RCT in cognitively normal adults aged 60–80. Tesamorelin maintained executive function (Trails B, verbal fluency) and verbal memory (CVLT) compared to placebo-treated decline. The effect was correlated with IGF-1 increase. No improvement above baseline — the benefit was preservation of function.

Significance

First RCT demonstrating GH-axis stimulation preserves cognition in aging. The neuroprotective (rather than enhancing) effect is clinically relevant given the trajectory of age-related cognitive decline. Supports the IGF-1/cognition hypothesis from epidemiological data.

Limitations

20-week duration — too short to assess long-term cognitive trajectory. Cognitive endpoints were secondary, not primary. No brain imaging (MRI volumetrics). Effect sizes were modest. Replication in non-GH-deficient elderly needed.

View on PubMed

Open Questions

Research gaps

Non-HIV Population Data Limited

FDA approval and most RCT data are in HIV-infected patients with lipodystrophy. Whether tesamorelin’s visceral fat, hepatic, and cognitive effects extend to the general population (age-related visceral adiposity, non-HIV NAFLD, normal aging cognition) requires dedicated trials. Extrapolation from HIV data is not straightforward due to the unique metabolic environment of HIV and antiretroviral therapy.

Long-Term Cancer Safety

Sustained IGF-1 elevation is a theoretical cancer risk factor. Tesamorelin’s post-marketing safety database is limited compared to recombinant GH (which has decades of surveillance). A dedicated cancer outcomes analysis over 5–10 years of use would be valuable, especially for prostate and breast cancer.

NAFLD Histology Needed

The Lancet HIV study used non-invasive fibrosis assessment. Regulatory approval for a NASH indication would require paired liver biopsies showing fibrosis regression or NASH resolution. No biopsy-based tesamorelin trial exists. This is the rate-limiting step for potential NAFLD/NASH approval.

Cognitive Trials Need Replication

The 2015 cognitive preservation trial was groundbreaking but single-center, 20 weeks, with modest effect sizes. A multi-center, 12–24 month trial with brain imaging (volumetric MRI, amyloid PET) endpoints is needed to establish clinical relevance for age-related cognitive decline or early neurodegeneration.

Optimal Treatment Duration Unknown

Benefits reverse upon discontinuation. There is no data on optimal cycling protocols, minimum effective treatment duration, or whether long-term continuous use is safe and effective. The FDA label does not specify a maximum treatment duration, leaving prescribers without clear guidance.

Cost & Access Barriers

Egrifta costs approximately $1,000–1,200/month. Insurance coverage for HIV lipodystrophy is variable, and off-label use (NAFLD, cognition, anti-aging) is rarely covered. Compounding pharmacies offer tesamorelin at lower cost, but quality and bioequivalence are not guaranteed for compounded versions.

Citations

References & further reading

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed

2. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV. 2019;6(12):e821-e830. PubMed

3. Baker LD, Barsness SM, Borber S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PubMed

4. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PubMed

5. Stanley TL, Chen CY, Branch KL, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. J Hepatol. 2020;73(6):1504-1513. PubMed

All Tesamorelin on PubMed → ← Back to Research Library